Other languages OBI Pharma, Inc.

Equities

4174

TW0004174008

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
61.3 ^TWD	+0.16%		0.00%	-11.67%

May. 10	Obi Pharma, Inc. Announces the Termination of License Agreement with Odeon for the Rights of Obi-999 and Obi-833 in China, Hong Kong and Macau	CI
Mar. 26	OBI Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Obi Pharma, Inc. Announces the Termination of License Agreement with Odeon for the Rights of Obi-999 and Obi-833 in China, Hong Kong and Macau	May. 10
OBI Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25
GNW-Adhoc: OBI Pharma kündigt Posterpräsentationen zu OBI-992 und zur GlycOBIT-AWK-Plattform auf der AACR-Jahrestagung 2024 an	Mar. 18
OBI Pharma annonce des présentations par affiches à la réunion annuelle de l’AACR 2024 pour OBI-992 et la plateforme CAM GlycOBI™	Mar. 18
OBI Pharma kündigt Posterpräsentationen zu OBI-992 und zur GlycOBI™-AWK-Plattform auf der AACR-Jahrestagung 2024 an	Mar. 18
Obi Pharma, Inc. Announces the Termination of Obi-3424-001 Trial While Continuing the Collaboration Of obi-3424 with Partners	Mar. 11
OBI Pharma, Inc. Announces Adagloxad Simolenin (OBI-822) Receives Positive 1st Interim Analysis Recommendation, Recommending the Continues of the Phase III TNBC Trial	Jan. 31
GNW-Adhoc: OBI Pharma gibt Freigabe des IND-Antrags für Phase-I/II-Studie mit OBI-992 durch FDA bekannt	Jan. 04
OBI Pharma reçoit l’agrément de la FDA à la suite de sa demande d’étude clinique de phase I/II pour OBI-992	Jan. 04
OBI Pharma gibt Freigabe des IND-Antrags für Phase-I/II-Studie mit OBI-992 durch FDA bekannt	Jan. 04
OBI Pharma, Inc. Announces OBI-992 TROP2 ADC Has Been Granted by US FDA to Proceed to Phase I/II Human Clinical Trial	Jan. 03
OBI Pharma, Inc. Announces Resignation of Yun Yen as Chairperson and Director, Effective December 29, 2023	Dec. 20
Obi Pharma, Inc. Files the Application of Phase I/II Human Clinical Trial for OBI-992 TROP2 ADC to US FDA	Dec. 01
OBI Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
OBI Pharma, Inc. Announces Internal Audit Officer Changes	Nov. 06
OBI Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07
OBI Pharma, Inc. Announces Executive Changes	23-08-07
OBI Pharma, Inc. Announces Appointment of Yun Yen as the Chairman	23-06-27
OBI Pharma, Inc. Announces Appointment of Yun Yen as Natural-Person Director	23-06-27
GNW-Adhoc: OBI Pharma gibt Wechsel in der Geschäftsführung bekannt - Dr. Heidi Wang als Chief Executive Officer ernannt	23-06-02

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages OBI Pharma, Inc.

Equities

4174

TW0004174008

Other languages

Filters